[使用 κ-阿片类受体激动剂治疗尿素性的临床研究进展]
Mei Yang1, Yupei Li1, Qinbo Yang1
1( 610041) General Practice Medical Center, West China Hospital, Sichuan University, Chengdu 610041.
概括
尿素性,在脏疾病中很常见,引起显著的痛苦. 像纳尔富拉芬这样的 κ-阿片类受体激动剂在有效管理这种严重的症状方面表现有前途.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 皮肤病学 皮肤病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 尿液性是慢性病 (CKD) 患者中普遍存在和致残的并发症.
- 它显著损害生活质量,导致抑郁和睡眠障碍.
- 目前对耐火性尿性的治疗方法往往有限.
研究的目的:
- 审查尿性的流行病学,病变发生和临床表现.
- 为了总结尿性的当前治疗策略.
- 详细介绍关于k-阿片类受体激动剂用于尿性管理的临床研究进展.
主要方法:
- 流行病学,病变发生和尿素性的临床症状的文献综述.
- 对 κ-阿片类受体激动剂的临床研究进行系统审查.
- 对纳尔富拉芬,迪菲利克法林和纳尔布芬的治疗疗效和安全数据的分析.
主要成果:
- 尿液性影响了大量的CKD患者,对他们的福祉产生了负面影响.
- κ-阿片类受体激动剂,包括纳尔富拉芬,迪菲利克法林和纳尔布芬,在减少耐火性尿素性方面表现出有效性.
- 这些药物似乎是安全的管理尿性.
结论:
- κ-阿片类受体激活剂代表了尿素性的有前途的治疗类.
- 进一步的研究支持它们在改善严重的CKD患者的生活质量方面的作用.
- 纳尔富拉芬,迪菲利克法林和纳尔布芬是这个不断变化的治疗领域的关键药物.
相关概念视频
Opioid Receptors: Overview
599
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
599
Analgesia and Pain Management
553
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
553
Opioid Analgesics: Synthetic and Semisynthetic Opioids
253
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
253
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
154
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
154
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
179
Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
179
Drug-Receptor Interaction: Agonist
2.4K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.4K


